Bizarre Patents
Microwave Oven With Removable Storage Cassette in Dashboard of Motor Vehicle
A microwave oven adapted for use within a motor vehicle dashboard area. The microwave oven has a removable storage cassette, and slidable platforms for securing and serving containers of beverages and foods.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7928062 | Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3) Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a der... | 04/19/2011 |
| 7919459 | Use of C5a receptor antagonist in the treatment of fibrosis This invention relates to the use of an antagonist of a G protein-coupled receptor in the prevention and/or treatment of fibrosis, such as the treatment of fibrosis associated with myocardial infarction or diabetes or certain pulmonary conditions. In a preferred emb... | 04/05/2011 |
| 7897565 | Compositions for HCV treatment The present invention concerns a pharmaceutical combination comprising a) a first agent which is a non-immunosuppressive cyclophilin-binding cyclosporine, e.g., a compound of formula I and b) a co-agent. Co-agents include, but are not limited to, interferons, a conj... | 03/01/2011 |
| 7851439 | EFTU inhibitors or aminothiazoles and their uses Organic compounds that are useful for the treatment, prevention and/or amelioration of diseases are described. ... | 12/14/2010 |
| 7825088 | Methods for the treatment of multiple myeloma Methods for treating multiple myeloma with inhibitors of CXCR4 are described. The decreased expression of CXCR4 on multiple myeloma cells according to the invention results in decreased homing of the cells to the bone marrow and a reduction in the development of the... | 11/02/2010 |
| 7772184 | Use of a cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said cyclosporin This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity. ... | 08/10/2010 |
| 7767645 | SH2 domain binding inhibitors Disclosed are compounds represented by the formula: or a pharmaceutically acceptable salt or isomer thereof, wherein R1-R6 are as defined in the specification. These compounds are targeted for use as i... | 08/03/2010 |
| 7763584 | Hepatitis C virus inhibitors Macrocyclic peptides having the general formula: are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed. ... | 07/27/2010 |
| 7759308 | Microparticles comprising somatostatin analogues Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles. ... | 07/20/2010 |
| 7749961 | Macrocyclic peptides active against the hepatitis C virus Compounds of formula (I): wherein R1, R2, X, R3, D, and the dotted line b are as defined herein; or a pharmaceutically acceptable salt or ester thereof, are useful as inhibitors of the HCV N... | 07/06/2010 |
| 7745400 | Prevention and treatment of ocular side effects with a cyclosporin Presently described are methods of administration and associated treatment of one or more ocular conditions using cyclosporine, or an analog or derivative thereof. The ocular conditions can be a result of treatment using other therapeutic agents, such as chemotherap... | 06/29/2010 |
| 7732404 | Pro-nanodispersion for the delivery of cyclosporin A novel cyclosporine formulation, which is a pro-nanodispersion at room temperature, featuring solid particles of a relatively large particle size (at least about 150 nm) and yet which is a nanodispersion at body temperature. ... | 06/08/2010 |
| 7732403 | Treatment of T-cell mediated diseases The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprisin... | 06/08/2010 |
| 7718611 | Cyclic nonapeptide amides The invention relates to cyclic nonapeptide amides and to methods for their preparation and to their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially bacterial infectious diseases. ... | 05/18/2010 |
| 7718612 | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of... | 05/18/2010 |
| 7709444 | Echinocandin pharmaceutical formulations containing micelle-forming surfactants Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound i... | 05/04/2010 |
| 7704948 | Pharmaceutical composition A stool softener and enteric coated bisacodyl form of a pharmaceutical composition. ... | 04/27/2010 |
| 7696166 | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders The present invention relates to methods of preventing or treating a mammal with a viral-induced disorder. The method involves administering to the mammal a therapeutically effective amount of a compound represented by Formula I, as shown below: ... | 04/13/2010 |
| 7696165 | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders The present invention relates to methods of preventing or treating a mammal with a viral-induced disorder. The method involves administering to the mammal a therapeutically effective amount of a compound represented by Formula I, as shown below: ... | 04/13/2010 |
| 7696167 | Cyclic peptide compound A cyclic peptide compound of the following general formula (I): Wherein R1, R2 and R3 are defined in the description, or a salt thereof. The compound (I) is useful for the prophylactic and/or therapeutic treatment of hepatitis C.... | 04/13/2010 |
| 7691813 | Cyclic peptide CXCR4 antagonists Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection. ... | 04/06/2010 |
| 7691812 | Methods for inhibiting growth of prolactin-responsive cancer cells with cyclosporine A or other cyclophilin inhibitors Methods are provided for inhibiting growth of prolactin-responsive cancer cells and treating prolactin-responsive malignancies via administration of an agent such as cyclosporine A which directly inhibits an enzymatic activity of a cyclophilin. ... | 04/06/2010 |
| 7687459 | Arylalkoxyl hepatitis C virus protease inhibitors The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) N... | 03/30/2010 |
| 7687458 | Pharmaceutical compositions of hydrophobic compounds This invention concerns novel methods of enhancing the solubility of a compound. Compositions prepared using such methods are also disclosed. Compositions prepared using the methods have various advantages over conventionally known compositions. ... | 03/30/2010 |
| 7678766 | Process for the preparation of cyclosporin derivatives The invention concerns a novel method for preparing an intermediate polyanion for preparing cyclosporin derivatives by treating a cyclosporin with a hexamethyldisilazane metal salt, optionally in the presence of a metal halide. The treated cyclosporin has one or sev... | 03/16/2010 |
| 7678765 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them The invention relates to aplidine derivatives of the general formula: which are useful for the treatment of tumors. ... | 03/16/2010 |
| 7671017 | Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV) A method of treating a patient having a HCV infection which method comprises administering to said patient a cyclosporin A or a cyclosporin A derivative in association with a conjugate of interferon to a water-soluble polymer in an amount effective to alleviate or e... | 03/02/2010 |
| 7662778 | Histone deacetylase inhibitor and process for producing the same HDAC inhibitor of the general formula (1) exhibits strong inhibitory activity against various subtype HDACs. The compound is useful as a medicinal agent for the treatment or prevention of HDAC 1, 4 and 6-related diseases. There is further provided a process for prod... | 02/16/2010 |
| 7662779 | Triazolyl macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) N... | 02/16/2010 |
| 7659246 | Treatment of osteoarthritis This invention relates to methods of treatment of osteoarthritis, and especially to treatment of this condition with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably... | 02/09/2010 |
| 7655625 | Methods of treating blepharospasm using cyclosporine components Methods of treating humans or animals afflicted with primary blepharospasm, for example, benign essential blepharospasm, or secondary blepharospasm not caused by an ocular surface disease or condition, are component to a human or animal so afflicted. ... | 02/02/2010 |
| 7655624 | Peptide and peptide mimetic conjugates with integrin-inhibitor properties The invention relates to compounds of formula (1) B-Q-X1, wherein B is bioactive cell adhesive mediating molecule. Q is absent or is an inorganic spacer molecule and X1 is an anchor molecule, selected from the group Lys-(CO—CH2—(... | 02/02/2010 |
| 7648961 | Use of somatostatin or one of its analogues for preparing a medicament intended to regulate the ovarian follicular reserve in non-menopausal women The invention primarily relates to the use of somatostatin or one of the agonistic analogs thereof for producing a medicament serving to regulate the ovarian follicular reserve and, in particular, to reduce the depletion of the ovarian follicular reserve over time i... | 01/19/2010 |
| 7632807 | Cyclosporin alkynes and their utility as pharmaceutical agents The compounds of the present invention are represented by the chemical structure found in Formula I: or a pharmaceutically acceptable salt thereof, with X, R0, and R1 defined herein. ... | 12/15/2009 |
| 7622440 | Cyclic natriuretic peptide constructs Cyclic constructs with an N-terminus and a C-terminus which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I: where R, R′, Q, Y, W, Z, J... | 11/24/2009 |
| 7605126 | Acylaminoheteroaryl hepatitis C virus protease inhibitors The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV)... | 10/20/2009 |
| 7582605 | Phosphorus-containing hepatitis C serine protease inhibitors The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A proteas... | 09/01/2009 |
| 7576057 | Cyclic peptides The invention relates to novel cyclic peptide derivatives of general formula (I): wherein A, B, R1 and R2 are as defined in the specification, pharmaceutically acceptable salts thereof, and their use a... | 08/18/2009 |
| 7569541 | Method for synthesizing conformationally constrained peptides, peptidomimetics and the use thereof as synthetic vaccines The present invention relates to methods for synthesizing conformationally constrained peptides and cyclic peptidomimetics obtainable by these methods which are conformationally constrained due an internal cross-link. This cross-link is formed between the side chain... | 08/04/2009 |
| 7560429 | Orodispersible dosage forms of desmopressin acetate Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin... | 07/14/2009 |
